Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)

AMD is a leading cause of vision loss across the G7 markets, with wet AMD accounting for most drug-treated cases. The market is dominated by IVT therapies such as Avastin, Eylea, Vabysmo, and Eylea HD, while the recent launch of Pavblu, a biosimilar of Eylea, adds competitive pressure. Unmet needs persist, particularly around reducing treatment burden and extending dosing intervals. The anticipated launch of TKIs (e.g., EyePoint’s Duravyu, Ocular Therapeutix’s Axpaxli) and gene therapies (i.e., AbbVie / Regenxbio’s sura-vec, Adverum / Eli Lilly’s ixo-vec, and 4DMT’s 4D-150), designed to deliver longer-lasting efficacy, is expected to reshape treatment dynamics over the next decade. In parallel, the GA pipeline is active with candidates such as Annexon’s vonaprument and Aviceda’s AVD-104 poised to expand options beyond Syfovre and Izervay for this underserved population. This report provides stakeholders with critical insight into how treatment patterns, competitive pressures, and emerging therapies will influence AMD market evolution across G7 countries through 2035.

Questions answered

• How will treatment patterns for wet AMD and GA evolve across the G7 markets over the next decade?
• What are the unmet needs driving physicians’ prescribing decisions?
• How will biosimilars and new entrants impact market share and pricing dynamics?
• What factors will shape adoption of emerging therapies in wet AMD and GA?
• How will competitive pressures and late-phase developments influence forecast growth?

Geography: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading retinal specialists; survey data collected for this and other Clarivate research

Epidemiology: Total prevalence of wet AMD and geographic atrophy (GA) by country, including diagnosed/drug-treated populations

Forecast: 10-year, annualized, drug-level sales and patient share of key dry and wet age-related macular degeneration therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

· Optimize your long-term disease and development strategy.

· Quantify market potential for your pipeline assets and those of your competitors.

· Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.

· Gauge the commercial outlook and impact of key market events.